Trial ChiCTR2000029387
Publication Huang YQ, Front Pharmacol, 2020
Primary outcome on the report: The difference in the interval from baseline (initiation of antiviral treatment) to SARS-CoV-2 nucleic acid negativity by nasopharyngeal swab among the three antiviral treatment groups, with each of these two tests at least 24 h apart.